Induction of apoptosis by the bis-Pt(III) complex [Pt2(2- mercaptopyrimidine)4Cl2]

Biochemical Pharmacology

Volumn 60, Issue 3, 2000, Pages 371-379

  González, Víctor M ^a   Fuertes, Miguel A ^a   Pérez Alvarez, María J ^a   Cervantes, Gemma ^b   Moreno, Virtudes ^b   Alonso, Carlos ^a   Pérez, José M ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Pt2(2 mercaptopyrimidine)4Cl2 ; Apoptosis; Cisplatin; Cytotoxicity; p53

Indexed keywords

ANTINEOPLASTIC AGENT; PLATINUM COMPLEX;

APOPTOSIS; ARTICLE; CELL STRUCTURE; CELL SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; DOSE TIME EFFECT RELATION; DRUG STRUCTURE; FIBROBLAST; HUMAN; HUMAN CELL; PRIORITY JOURNAL; TUMOR CELL LINE;

ANNEXINS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL NUCLEUS; CELL SIZE; CELLS, CULTURED; DNA FRAGMENTATION; ELECTROPHORESIS, AGAR GEL; HELA CELLS; HL-60 CELLS; HUMANS; ORGANOPLATINUM COMPOUNDS; PLATINUM COMPOUNDS; PYRIMIDINES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0343674081     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(00)00329-4     Document Type: Article

References (31)

1. Passini A., Zunino F. New cisplatin analogues. On the way to better antitumor agents. Angew Chem Int Ed Engl. 26:1987;615-624.
2. Kelland L.R. New platinum antitumor complexes. Crit Rev Oncol Hematol. 15:1993;191-219.
3. 2O complex inhibits the B to Z transition. Mol Pharmacol. 85:1999;770-778.
4. O'Neill C.F., Ormerod M.G., Robertson D., Titley J.C., Cumber-Walsweer Y., Kelland L.R. Apoptotic and non-apoptotic cell death induced by cis and trans analogues of a novel ammine(cyclohexylamine)dihydroxodichloro platinum(IV). Br J Cancer. 74:1996;1037-1045.
5. Pérez J.M., Camazón M., Alvarez-Valdés A., Quiroga A.G., Kelland L.R., Alonso C., Navarro-Ranninger C. Synthesis, characterization and DNA modification induced by a novel Pt(IV)-bis(monoglutarate) complex which induces apoptosis in glioma cells. Chem Biol Interact. 117:1999;99-115.
6. Natile G., Intini F.P., Pacifico C. Diplatinum(III) complexes Chemical species more widely spread than suspected . Lippert B. Cisplatin, Chemistry and Biochemistry of a Leading Anticancer Drug. 1999;429-453 Verlag, Basel.
7. Kerr J.F., Wyllie A.H., Currie A.R. Apoptosis A basic biological phenomenon with wide-ranging implications in tissue kinetics . Br J Cancer. 26:1972;239-257.
8. Ellis R.E., Yuan J., Horvitz H.R. Mechanisms and functions of cell death. Annu Rev Cell Biol. 7:1991;663-698.
9. Wyllie A.H., Kerr J.F., Currie A.R. Cell death The significance of apoptosis . Bourne G.H., Danielli F.J., Jeon K.W. International Review of Cytology. Vol. 68:1980;251-306 Academic Press, New York.
10. Steller H. Mechanisms and genes of cellular suicide. Science. 267:1995;1445-1449.
11. Hickman J.A. Apoptosis induced by anticancer agents. Cancer Metastasis Rev. 11:1992;121-139.
12. Dive C., Wyllie A.H. Apoptosis and cancer chemotherapy. Hickman J.A., Tritton T.R. Frontiers in Pharmacology. 1993;21-56 Blackwell Scientific Press, Oxford.
13. Lowe SW, Ruley HE, Jacks T and Housman DE, p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74: 957-967, 1993.
14. Schulze-Osthoff K., Ferrari D., Los M., Wesselborg S., Peter M.E. Apoptosis signaling by death receptors. Eur J Biochem. 254:1998;439-459.
15. Eastman A. Activation of programmed cell death by anticancer agents Cisplatin as a model system . Cancer Cells. 2:1990;275-280.
16. Cervantes G., Prieto M.J., Moreno V. Antitumor activity of a Pt(III) derivative of 2-mercaptopyridine. Metal-Based Drugs. 4:1997;7-16.
17. Onoa G.B., Cervantes G., Moreno V., Prieto M.J. Study of the interaction of DNA with cisplatin and other Pd(II) and Pt(II) complexes by atomic force microscopy. Nucleic Acids Res. 26:1998;1473-1480.
18. Murray M., Cunningham J., Parada L., Dautry F., Lebowitz P., Weinberg R. The HL-60 transforming sequence A ras oncogene coexisting with altered myc sequences in hematopoietic tumors . Cell. 33:1983;749-757.
19. O'Connor P., Jackman J., Bae I., Myers T.G., Fan S., Muton M., Scudiero D.A., Monks A., Sausville E.A., Weinstein J.N., Friend S., Fornace A.J. Jr, Kohn K.W. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res. 57:1997;4285-4300.
20. Kelland LR, Mistry P, Abel G, Loh SY, O'Neill CF, Murrer BA and Harrap KR, Mechanism-related circumvention of acquired cis-diamminedichloroplatinum(II) resistance using two pairs of human ovarian carcinoma cell lines by ammine/amine platinum(IV) dicarboxylates. Cancer Res 52: 3857-3864.
21. Alley M.C., Scudiero D.A., Monks A., Hursey M.L., Czerwinski M.J., Fine D.L., Abbott B.J., Mayo J.G., Shoemaker R.H., Boyd M.R. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res. 48:1988;589-601.
22. Pérez J.M., Quiroga A.G., Montero E.I., Alonso C., Navarro-Ranninger C. A cycloplatinated compound of p-isopropylbenzaldehyde thiosemicarbazone and its chloro-bridged derivative induce apoptosis in cis-DDP resistant cells which overexpress the H-ras oncogene. J Inorg Biochem. 73:1999;235-243.
23. Wright S.C., Kumar P., Tam A.W., Shen N., Varma M., Larrick J.W. Apoptosis and DNA fragmentation precede TNF-induced cytolisis in U-937 cells. J Cell Biochem. 48:1992;344-355.
24. Crook T., Wrede D., Tidy J.A., Mason W.P., Evans D.J., Vousden K.H. Clonal p53 mutation in primary cervical cancer Association with human-papillomavirus-negative tumours . Lancet. 339:1992;1070-1073.
25. Gorczyca W., Gong J., Ardelt B., Traganos F., Darzynkiewicz Z. The cell cycle related differences in susceptibility of HL-60 cells to apoptosis induced by various antitumor agents. Cancer Res. 53:1993;3186-3192.
26. Chabner B.A., Myers C.E. Clinical pharmacology of cancer chemotherapy. DeVita V.T., Hellman S., Rosenberg S.A. Cancer Principles and Practice of Oncology . 1989;349-395 JB Lippencott, Philadelphia.
27. Mellish K.J., Kelland L.R., Harrap K.R. In vitro platinum drug chemosensitivity of human cervical squamous cell carcinoma cell lines with intrinsic and acquired resistance to cisplatin. Br J Cancer. 68:1993;240-250.
28. Dabholkar M., Reed E. Cisplatin. Pinedo H.M., Chabner B.A. Cancer Chemotherapy and Biological Response Modifiers. Vol. 16:1996;88-110 Elsevier, Amsterdam.
29. Fritsche M., Haessler C., Brandner G. Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging agents. Oncogene. 8:1993;307-318.
30. Perego P., Gravola M., Righetti J.C., Supino R., Caserini C., Delia P., Pierotti M.A., Miyashita T., Reed J.C., Zunino F. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. Cancer Res. 56:1996;556-562.
31. Gallagher W.M., Cairney M., Schott B., Roninson I.B., Brown R. Identification of p53 genetic suppressor elements which confer resistance to cisplatin. Oncogene. 14:1997;185-193.